Oryzon to Present Updated Iadademstat Clinical Data at ASH 2026
Oryzon Genomics said it will present updated clinical data for iadademstat in hematological malignancies at ASH 2026.
Related stories
General Motors shares hit record high, up 4%
M impact | EQUITY | Nov 04, 2026, 03:33 PM UTC
SolarEdge Reports Q3 Revenue of $326.1 Million, Adjusted EPS of $0.29
Third-quarter revenue was $326.1 million, in line with the midpoint of prior guidance. Adjusted EPS was $0.29 versus FactSet consensus of $0.04. SolarEdge forecast fourth-quarter r
M impact | EQUITY | Nov 04, 2026, 03:33 PM UTC
Kempower Reports Q3 Revenue Decline and Lowers 2026 Guidance
Kempower reported a 10% revenue decline and negative operative EBIT in Q3 2026, citing weakening charging investment. It lowered full-year 2026 guidance, while reporting a €128 mil
M impact | EQUITY | Nov 04, 2026, 03:33 PM UTC
Skue Sparebank Reports Q3 Pretax Profit of NOK 102.5 Million
M impact | EQUITY | Nov 04, 2026, 03:33 PM UTC
Microsoft Shares Hit Record High, Up 6.1%
M impact | EQUITY | Nov 04, 2026, 03:32 PM UTC
IMFA Q2 Profit Jumps 51% to Rs 149 Crore
Indian Metals & Ferro Alloys Ltd reported Q2 FY27 profit after tax of Rs 148.77 crore, compared with Rs 98.77 crore a year earlier. Revenue rose 35%.
M impact | EQUITY | Nov 04, 2026, 03:32 PM UTC